antisense

Fierce Pharma

Sarepta, despite key trial flop, will seek full nod for DMD meds

Sarepta’s Vyondys 53 and Amondys 45 failed to show a statistically significant difference versus placebo on a key measurement of DMD patient mobility.

Angus Liu Nov 4, 2025 7:56am

Ionis rare disease candidate ekes out phase 3 win

Sep 22, 2025 10:46am

An artists 3D rendering of cancerous blood cells among healthy red blood cells The cells fill the image and are of various

Ono pays $280M upfront for Ionis' phase 2 blood cancer med

Mar 12, 2025 6:30am

An artists depiction of DNA molecules made up of tiny particles

Oligonucleotide stops gene expansion driving Huntington's: study

Feb 12, 2025 2:00pm

Brain and money connected by a thread on a white background

Sanofi inks $400M biobucks deal for Alloy's antisense platform

Jan 8, 2025 5:08am

Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks

Oct 24, 2024 8:55am